

> 流行病學


# TUBERCULOSIS

流行病學

• U.S.: 10–15 million infected (15× ↑ risk if foreign-born or minority); worldwide: ~2 billion

• Multidrug-resistant (**MDR**) **TB:** resistant to INH & rifampin. Can occur as 1° infxn.

• Extensively drug-resistant **(XDR) TB** resistant to INH, RIF, FQ, and injectables

• Risk factors (_NEJM_ 2011;364:1441)

_Acquisition:_ immigrant from high-prevalence area, homeless, IVDU or medically underserved, resident or worker in jail or long-term facility, healthcare worker, close contact to Pt with active TB

_Reactivation:_ risk is 5% in first 2 yr, 5–10% over lifetime, but higher if HIV ⊕, immunosupp. incl. biologics, CKD (HD), uncontrolled DM, cancer, transplant, malnourished, underweight, smoker, IVDU, alcohol

Microbiology & natural history

• Transmission of _Mycobacterium tuberculosis_ via small-particle aerosols (droplet nuclei)

• 90% of infected normal hosts will never develop clinically evident disease

• Localized disease: healing & calcification _or_ progressive 1° TB (at site of infection)

• Hematogenous spread: latent infection ± reactivation TB _or_ progressive dissem. TB

Screening for latent TB

• **Whom to screen:** high-prevalence and high-risk populations (HIV ⊕ 病人 should be tested as part of initial evaluation and annually thereafter)

• **How to screen**

• **IFN-γ release assays (IGRA):** Ag-stimulated IFN-γ release from patient’s T-cells. Preferred to PPD due to ↑ Sp in BCG vaccine 病人 (_Annals_ 2008;149:177).

• **Tuberculin skin test (TST or also known as PPD):** inject purified protein interdermally then examine for wheal 48–72 hrs later. Interpret based on max diameter of induration.

<table><colgroup><col> <col></colgroup><tbody><tr><td><p><b>Size of Reaction</b></p></td><td><p><b>Persons considered to have</b> <span>⊕</span> <b>test</b> <span>(<i>NEJM</i> 2002;347:1860)</span></p></td></tr><tr><td><p>&gt;<b>5 mm</b></p></td><td><p>HIV ⊕ or immunosupp (eg, prednisone 15 mg/d × &gt;1 mo)</p><p>Close contacts of Pt with active TB; CXR with apical fibrosis c/w TB</p></td></tr><tr><td><p>&gt;<b>10 mm</b></p></td><td><p>All other high-risk or high-prevalence populations</p><p>Recent conversion (↑ in induration by &gt;10 mm in last 2 y)</p></td></tr><tr><td><p>&gt;<b>15 mm</b></p></td><td><p>Everyone else</p></td></tr><tr><td><p>False ⊖</p></td><td><p>Faulty application, anergy (including from active TB), acute TB</p><p>(2–10 wk to convert), acute non-TB mycobacteria (NTM), malignancy</p></td></tr><tr><td><p>False ⊕</p></td><td><p>Improper reading, cross-reaction with NTM, BCG vaccination (although usually &lt;10 mm by adulthood)</p></td></tr><tr><td><p>Booster effect</p></td><td><p>↑ induration b/c immunologic boost by prior skin test in prev sensitized individual (by TB, NTM or BCG). Test ⊖ → ⊕ but <i>not</i> true conversion due to <i>recent</i> infxn. 2<sup>nd</sup> test true baseline. Can be 1 y after initial test.</p></td></tr></tbody></table>

• **Neither screening test rules in/out active TB.** Use both IGRA & PPD combined to ↑ Se (to 80–90%). Relies on host immune system, therefore limited Se in immunocompromised (_J Clin Epi_ 2010;63:257; _CID_ 2011;52:1031).

臨床表現 (_Lancet_ 2016;387:1211)

• **Primary TB pneumonia:** middle or lower lobe consolidation, ± effusion, ± cavitation

• **TB pleurisy:** can occur with primary or reactivation. Due to breakdown of granuloma with spilling of contents into pleural cavity and local inflammation. **Pulmonary effusion** ± pericardial and peritoneal effusions (tuberculous polyserositis).

• **Reactivation TB pulmonary disease:** apical infiltrate ± volume loss ± cavitation

• **Miliary TB:** acute or insidious; due to hematogenous dissemination; usually in immunosupp, DM, EtOH, elderly or malnourished. **Constitutional sx** (fever, night sweats, weight loss) usually prominent. Pulm disease with millet seed-like lesions (2–4 mm) on CXR or chest CT (latter more Se) present in 60–80% of those with miliary TB.

• **Extrapulmonary TB:** lymphadenitis, pericarditis, peritonitis, meningitis, nephritis ± sterile pyuria, osteomyelitis (vertebral = Pott’s disease), hepatitis, splenitis, cutaneous, arthritis

• **TB and HIV:** HIV ⊕ at ↑ risk infxn, progressive 1° infxn & reactivation. Risk of progression from infxn to disease >8–10%/y, higher risk with ↓ CD4. Reinfection (also with MDR) significant, esp. in hyperendemic areas.

Diagnostic studies for active TB (_high index of suspicion is key!_)

• **AFB smear** (rapid dx) and **culture** (↑ Se & allows sensitivity testing) of sputum, BAL, pleura, etc.; _avoid FQ_ if considering TB (can compromise dx yield)

• Gene Xpert PCR (rapid dx) can also detect rifampin resistance; validated on nonbloody sputum only. Sp 98% & Se 74% independent of HIV status (_AJRCCM_ 2014;189;1426).

• PCR: 94–97% Se c/w smear; 40–77% Se c/w culture (_JAMA_ 2009;301:1014)

• CXR: classically fibrocavitary apical disease in reactivation vs. middle & lower lobe consolidation in 1° TB but distinction imperfect. HIV ⊕ assoc. with nonapical disease regardless of timing (_JAMA_ 2005;293:2740).

• Adenosine deaminase testing: useful in extrapulmonary sites; best validated for ascites

治療 of latent TB

• Treat 病人 who are ⊕ based on guidelines or any exposed HIV ⊕ or immunocompromised Pt (_NEJM_ 2015;372:2127; _Eur Respir J_ 2015;46:1563)

• **排除 active disease** in any Pt with suggestive signs and symptoms before starting INH (cough, fever, nightsweats), CXR (though may be 正常 in immunosupp.)

<table><colgroup><col> <col></colgroup><tbody><tr><td><p><b>Scenario</b></p></td><td><p><b>Prophylaxis Regimen</b></p></td></tr><tr><td><p>PPD/IGRA ⊕ (regardless of HIV status), or contact case INH resistant</p></td><td><p>1<sup>st</sup> line: Rifampin × 4 mo (non-inferior to INH, greater adherence and lower hepatotoxicity) <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>8;5:440)</span>.</p><p><i>Alternative:</i> [INH 5 mg/kg + vitamin B6 × 9 mo] <i>or</i> [INH + Rifapentine weekly × 12 wk]</p></td></tr><tr><td><p>Contact case known or suspected to have MDR TB</p></td><td><p>No proven regimen: ? PZA + EMB, ? PZA + FQ</p></td></tr></tbody></table>

(INH, isoniazid; RIF, rifampin; PZA, pyrazinamide; EMB, ethambutol; FQ, fluoroquinolone)

• ✔ LFTs monthly if receiving INH (risk ↑ with age; _Chest_ 2005;128:116): if 5× ULN _or_ sx → stop TB meds & re-eval

### Patient isolation

• Decision based on likelihood. Consider when cough, dyspnea, hemoptysis + 1 risk factor (HIV ⊕, foreign born, substance use disorder, homeless, recent incarceration, prior TB or exposure).

• Discontinue if alternative dx, AFB smear neg ×3, or TB treated for 2 wk & AFB neg

治療 of active tuberculosis (_NEJM_ 2015;373:2149; _Lancet_ 2016;387:1211)

• 治療 requires several drugs to prevent resistance (see below)

• **Suspect MDR TB** if prior TB Rx, travel to area with ↑ rates of MDR (India, China, Russia, South Africa), exposure to person with likely MDR-TB, poor Rx adherence, INH resis. in community ≥4% (includes most of U.S.), extrapulm. TB, HIV ⊕ (_NEJM_ 2008;359:636)

• Screen for HIV. If ⊕ → consult ID re: timing of concurrent HIV Rx

• “Paradoxical _worsening_” of sx can occur after starting Rx. More common with extrapulm TB & more frequent/severe with concurrent immune reconstitution (eg, HIV ⊕ 病人 started on ARVs, 病人 taken off immunosuppression). _Must 排除 Rx failure_ (repeat Cx, imaging, etc.).

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Antituberculous Medications</b></p></td></tr><tr><td><p><b>Drug</b></p></td><td><p><b>Dose</b></p></td><td><p><b>Adverse Effects<a id="st11"></a><a href="text/part0011_split_007.html#sst11">*</a></b></p></td></tr><tr><td><p>Isoniazid (INH)</p></td><td><p>300 mg PO qd</p></td><td><p>Hepatitis, periph neuropathy (↓ risk by suppl. vit B<sub>6</sub>), drug-induced lupus</p></td></tr><tr><td><p>Rifampin (RIF)</p></td><td><p>600 mg PO qd</p></td><td><p>Orange tint of body fluids, GI upset, hepatitis, hypersensitivity, fever, drug interactions, avoid EtOH</p></td></tr><tr><td><p>Pyrazinamide (PZA)</p></td><td><p>25 mg/kg PO qd</p></td><td><p>Hepatitis, hyperuricemia, arthritis</p></td></tr><tr><td><p>Ethambutol (EMB)</p></td><td><p>15–25 mg/kg PO qd</p></td><td><p>Optic neuritis</p></td></tr><tr><td><p>Streptomycin (SM)</p></td><td><p>15 mg/kg IM qd</p></td><td><p>Ototoxicity, nephrotoxicity</p></td></tr><tr><td><p>Amikacin (AMK)</p></td><td><p>15 mg/kg IM qd</p></td><td><p>Ototoxicity, nephrotoxicity</p></td></tr><tr><td><p>Quinolone (moxifloxacin)</p></td><td><p>400 mg PO qd</p></td><td><p>GI upset, tendinopathy, ↑ QTc</p></td></tr></tbody></table>

[\*](text/part0011_split_007.html#st11)Risk of hepatitis ↑ with pre-existing liver disease. Consult ID if mod to severe liver disease, and consider holding/replacing PZA or INH.

<table><colgroup><col> <col></colgroup><tbody><tr><td><p><b>Scenario</b></p></td><td><p><b>Antituberculous 治療 Regimens</b></p></td></tr><tr><td><p><b>Pulmonary TB</b></p><p><b>≥4% INH-resist. in community</b> (includes most of U.S.)</p></td><td><p>INH + RIF + PZA + (EMB) until suscept. known</p><p>If <i>sensitive</i> to INH &amp; RIF → INH + RIF + PZA × 2 mo, <i>then</i> → INH + RIF × 4 mo</p><p>If <i>resistant</i>, see next row</p></td></tr><tr><td><p><b>Drug-resistant TB</b> (INH-R, RIF-R or MDR/XDR)</p></td><td><p><i>Consult ID specialist</i></p><p><span>(</span><span><i>NEJM</i></span> <span>2008;359:636)</span></p></td></tr><tr><td><p><b>Extrapulmonary TB</b></p></td><td><p><i>Consult ID specialist</i></p></td></tr><tr><td><p><b>TB in HIV</b> ⊕ <b>patient</b></p></td><td><p><i>Consult ID specialist</i></p></td></tr></tbody></table>

Individualize duration based on host, disease form, and rate of clinical/microbiologic improvement
